Filing Flows › Companies › Cytokinetics › Timeline
Cytokinetics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−11.0% to $53.69
Cytokinetics (CYTK) stock fell 11% over the last 252 sessions, to $53.69. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 11 Form 144 notices of planned sales, and the company filed 1 material 8-K. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 2.6% | +2.1% (+0.4% vs SPY) | — | — |
| Oct 20, 2026 | Form 144 | Form 144: Fady Malik plans to sell $1.0M | +2.1% (+1.7% vs SPY) | −3.1% (−3.0% vs SPY) | — |
| Oct 12, 2026 | Form 144 | Form 144: Robert Blum plans to sell $1.4M | −0.2% (−0.1% vs SPY) | −1.5% (+0.5% vs SPY) | — |
| Sep 15, 2026 | Form 144 | Form 144: Robert I. Blum plans to sell $7.1M | −4.4% (−4.0% vs SPY) | −7.0% (−8.9% vs SPY) | −16.2% (−18.7% vs SPY) |
| Sep 11, 2026 | Form 144 | Form 144: Robert Landry plans to sell $147K | +0.2% (−0.7% vs SPY) | −5.2% (−5.8% vs SPY) | −15.7% (−18.7% vs SPY) |
| Sep 1, 2026 | Form 144 | Form 144: B Lynne Parshall plans to sell $355K | +0.7% (+1.4% vs SPY) | +6.1% (+6.2% vs SPY) | −7.3% (−7.0% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 6.3% | +3.1% (+3.3% vs SPY) | −4.2% (−4.5% vs SPY) | −6.4% (−6.9% vs SPY) |
| Jul 30, 2026 | Form 144 | Form 144: Andrew Callos plans to sell $1.9M | +2.6% (+0.9% vs SPY) | +0.6% (−4.8% vs SPY) | −0.6% (−6.2% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Fady Malik plans to sell $2.1M | 0.0% (+0.5% vs SPY) | −4.0% (−3.7% vs SPY) | −8.5% (−11.1% vs SPY) |
| Jul 1, 2026 | Form 144 | Form 144: Robert Blum plans to sell $4.5M | +0.1% (+0.2% vs SPY) | −0.4% (−0.2% vs SPY) | −5.8% (−5.1% vs SPY) |
| Jun 29, 2026 | Form 144 | Form 144: Sung Lee plans to sell $781K | +6.0% (+4.4% vs SPY) | +4.0% (+1.0% vs SPY) | −3.4% (−5.0% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Sung Lee plans to sell $541K | +1.7% (+2.4% vs SPY) | +6.8% (+5.4% vs SPY) | −0.2% (−0.9% vs SPY) |
| Jun 24, 2026 | Form 144 | Form 144: Sung Lee plans to sell $3.1M | +1.5% (+1.5% vs SPY) | +6.3% (+4.5% vs SPY) | +2.4% (+1.8% vs SPY) |
| May 5, 2026 | Earnings | Earnings: missed the EPS estimate by -1.3% | +15.5% (+14.7% vs SPY) | +12.1% (+9.2% vs SPY) | +6.8% (+1.9% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: missed the EPS estimate by -9.7% | +2.7% (+1.9% vs SPY) | −10.5% (−11.1% vs SPY) | −12.9% (−8.7% vs SPY) |
| Nov 14, 2025 | 8-K | Directors and officers: departures, appointments, pay | +0.8% (+1.7% vs SPY) | −1.5% (+0.4% vs SPY) | −6.9% (−7.9% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Cytokinetics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.